Thursday, January 05, 2017 9:19:41 PM
Artemisinin-based Combination Therapies (ACTs), are recommended by the World Health Organization (“WHO”) as the primary first-line treatment for malaria and have saved thousands of lives, especially among children.
Prior to Amyris's revolutionary breakthrough, the primary natural source for artemisinin was the Chinese Sweet Wormwood plant, which is difficult, expensive and time-consuming to cultivate and extract artemisinin from thereby preventing millions of people in the developing world from receiving critical ACTs. Through the partnership, Amyris made available artemisinic acid-producing yeast strains to Sanofi on a royalty-free basis via OneWorld Health and approximately 120 million treatments were cost effectively produced by October 2014.
Amyris continues to work to ensure access to affordable malaria treatments to save lives. In April 2016, the company announced that it was once again partnering with the Foundation via an investment from it to fund efforts focused on continued production of high quality and secure supplies of artemisinic acid and amorphadiene to be converted to artemisinin for use in ACTs.
Recent AMRSQ News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/22/2024 05:15:39 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 02/10/2024 02:24:29 AM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 02/10/2024 02:14:56 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2024 09:42:49 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 12/14/2023 09:34:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/13/2023 10:23:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/29/2023 09:43:26 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM